id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-E-6016-0003,FDA,FDA-2017-E-6016,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2017-10-17T04:00:00Z,2017,10,2017-10-17T04:00:00Z,,2017-10-17T20:13:28Z,,0,0,0900006482bd61b5
FDA-2017-E-6016-0002,FDA,FDA-2017-E-6016,Letter from U.S. Patent and Trademark Office,Other,Application,2017-10-04T04:00:00Z,2017,10,2017-10-04T04:00:00Z,,2017-10-04T12:38:39Z,,0,0,0900006482b9ad96
FDA-2017-E-6016-0001,FDA,FDA-2017-E-6016,Patent Extension Application from McDermott Will & Emerly LLP (on behalf of KAI Pharmaceuticals Inc),Other,Application,2017-10-04T04:00:00Z,2017,10,2017-10-04T04:00:00Z,,2017-10-04T12:32:24Z,,0,0,0900006482b9ad3f